Wordt geladen...
RIPK2 as a New Therapeutic Target in Inflammatory Bowel Diseases
Inflammatory bowel diseases (IBDs) are becoming more frequent worldwide. A significant fraction of patients with IBD are refractory to various types of therapeutic biologics and small molecules. Therefore, identification of novel therapeutic targets in IBD is required. Receptor-interacting serine/th...
Bewaard in:
| Gepubliceerd in: | Front Pharmacol |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8079979/ https://ncbi.nlm.nih.gov/pubmed/33935757 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2021.650403 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|